LDU (at week 2) to determine the extent of initial parasite killing (12) . The remaining 16 treated mice were randomly divided into four groups to receive, for the next 9 weeks, either no further treatment or single doses of miltefosine (25 mg/kg) given twice weekly, once weekly, or every 2 weeks. Twelve weeks after infection, liver parasite burdens were determined for all animals.
Results and discussion. Between week 2 and week 3, the period during which miltefosine was initially administered, liver parasite burdens increased in untreated nude mice from 2,124 Ϯ 269 (Fig. 1 ) to 2,994 Ϯ 212 LDU (mean Ϯ the standard error of the mean [SEM]) (n ϭ 8, data not shown). In mice treated for 5 days, LDU (mean Ϯ SEM) at week 3 were reduced to 496 Ϯ 87, indicating 77% initial killing 1 week after therapy began (Fig. 1) . Treated mice were then given either no additional miltefosine or single doses twice per week, once per week, or every second week for the next 9 weeks. As shown in Fig. 1 , parasite replication resumed in treated mice that were given no additional drug, and liver burdens at week 12 were 3.5-fold higher than those at week 3. While miltefosine admin- istered biweekly did not prevent recurrence of visceral replication, treatment given once or twice weekly was clearly active in suppressing infection for the duration of the experiment. Histologic examination of the livers at week 12 confirmed these effects (Fig. 2) .
Intracellular Leishmania organisms are probably seldom, if ever, entirely eradicated even from healthy hosts by either antileishmanial chemotherapy or the T-cell-dependent, cytokine-driven mechanism which develops to regulate successful acquired resistance and prevention of relapse in visceral infection (3, 9, 10, 13, 14, 16) . In T-cell-depleted or -deficient hosts with kala-azar, such as individuals with advanced human immunodeficiency virus disease (1) or immunosuppressed transplant recipients (5) , not only may an initial response to treatment be difficult to induce, but also relapse after such an apparent response is frequent once therapy is discontinued (1, 2, 5, 7, 8, 11, 13, 15; Davidson and Russo, Letter, Clin. Infect. Dis., 1994).
Although not yet well studied, current evidence regarding AIDS-related kala-azar suggests that maintenance treatment with once-monthly injections of pentavalent antimony may suppress recurrent infection (15) ; however, monthly pentamidine injections (7) or daily oral allopurinol use appears to have little effect (15) .
While it still needs to be tested in patients coinfected with human immunodeficiency virus, miltefosine is remarkably active in kala-azar (6, 17, 18) and has additional advantages: (i) a long circulating half-life (ϳ8 days) (17) and (ii) experimental antileishmanial efficacy which is direct and does not require a host T-cell-dependent response for full expression (12) . The results reported here suggest that miltefosine has promise as a convenient oral treatment to suppress or prevent relapse of visceral infection in the T-cell-deficient host.
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